RocheDiabetes Care has extended its offering beyond blood glucose monitoring (BGM), insulin delivery and digital solutions into continuous glucose monitoring (CGM), following CE marking this summer of its Accu-Chek Smartguide solution.
Roche Uses Its CGM To Target Unmet Needs In Diabetes Control
Glucose Level Algorithms Key Positioning In CGM Sector
CE marking for its Accu-Chek Smartguide continuous glucose monitor means Roche is on the cusp of challenging existing major players in Europe with a device whose predictive algorithms can help sufferers plan and prepare longer into the future.
More from Innovation
More from In Vivo
• By
Lundbeck CEO Charl van Zyl spoke with In Vivo about the Danish company’s multipronged transformation, one that involves a rethink of company culture, pipeline strategy and a sharpened focus on innovation in rare neurological disorders.
• By
Antag CEO Joerg Moeller talked to In Vivo about the young company’s gilded roots, and how its GIP receptor antagonist asset will differentiate in the crowded obesity market.
• By
Despite the significant presence of East Asian professionals in the pharmaceutical industry, their representation in top leadership roles remains disproportionately low. This disparity can be attributed to cultural bias, limited access to influential networks, and systemic barriers within corporate structures.